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In the present study we examined the ability of the amino acid derivative LTX-401 to induce
cell death in cancer cell lines, as well as the capacity to induce regression in a murine mela-
noma model. Mode of action studies in vitro revealed lytic cell death and release of danger-
associated molecular pattern molecules, preceded by massive cytoplasmic vacuolization
and compromised lysosomes in treated cells. The use of a murine melanoma model demon-
strated that the majority of animals treated with intratumoural injections of LTX-401 showed
complete and long-lasting remission. Taken together, these results demonstrate the poten-
tial of LTX-401 as an immunotherapeutic agent for the treatment of solid tumors.
Introduction
Host defense peptides (HDPs) are naturally occurring peptides with important antimicrobial
and immunomodulatory functions, as part of the innate immune system in virtually all species
of animals [1–3]. Several HDPs are reported to exhibit oncolytic properties, also termed onco-
lytic peptides, with an ability to cause the lysis of cancer cells [4]. This ability has been con-
firmed by several synthetically designed peptides [4–7]. In the present study, the effect of a
cytolytic compound, LTX-401, was investigated. LTX-401 is a small amphipathic β(2,2)-amino
acid-derived antitumor molecule with an amphipathic conformation. Based on structure-activ-
ity-relationship (SAR) studies on short cationic peptides (<9 amino acid residues), it was dis-
covered that the introduction of large lipophilic groups compensated for the peptide length [8].
Additionally, by coupling two aromatic side-chains to the same carbon atom, the length could
be further reduced to a minimum without losing cytotoxic activity. These discoveries led to the
production and synthesis of a panel of β-peptidomimetics to help confirm the pharmacophore
model of short cationic peptides [9], which dictates that such compounds should contain
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cationic-charged residues, in addition to bulky and lipophilic moieties for optimal activity [3,
9]. LTX-401 was chosen as the lead compound in this panel. The purpose of the present study
was to investigate the cytotoxic mode of LTX-401 in vitro, including the ability to induce the
release of danger-associated molecular pattern molecules (DAMPs), as well as the effect of
LTX-401 treatment in an experimental murine B16 melanoma model.
Material and Methods
Reagents
LTX-401 (Mwnet = 367.53) was synthetized on request by Synthetica AS (Oslo, Norway). The
chemical structure is shown in Fig 1.
Cell Cultures
JM1, a rat hepatocellular carcinoma, HEPG2 and BEL7402, both human hepatocellular carci-
nomas, were kindly provided by Dr. Pål-Dag Line, Director, Department of Transplantation
Medicine, Oslo University Hospital. B16F1 (ATCC, CRL-6323), a murine skin malignant
melanoma, MDA-MB-435S (HTB-129), a human malignant melanoma originating from a
breast metastases, Malme-3M (HTB-64), a human malignant melanoma derived from a lung
metastases, MRC-5 (ATCC, CCL-171), normal human lung fibroblasts, SK-N-AS (ATCC,
CRL-2137), a human neuroblastoma cell line derived from a bone marrow metastases, HT-
29 (ATCC, HTB-38), a human colorectal adenocarcinoma and HUV-EC-C (ATCC, CRL-
1730), a human vascular endothelium cell line, were all purchased from the American Type
Culture Collection (ATCC-LGC Standards, Rockville, MD, USA). HaCat, a human keratino-
cyte cell line, was kindly provided by Dr. Ingvild Pettersen, Department of Host Microbe
Interactions, University of Tromsø. A375, a malignant melanoma cell line of human origin,
was purchased from Public Health England (PHE Culture Conditions, Porton, Down, Salis-
bury, UK). JM1, A375, BEL7402, HEPG2 and B16F1 were all maintained in culture media
consisting of DMEM (high glucose), while SK-N-AS, HT-29 and MDA-MB-435S were cul-
tured in an RPMI-1640 medium containing 2mM L-glutamine and sodium bicarbonate.
Malme-3M was cultured in RPMI-1640, containing 4 mM L-glutamine and 20% FBS (fetal
bovine serum). Lastly, the three non-malignant cell lines, HUV-EC-C, MRC-5 and HaCat,
were cultured, respectively, using the EGM-2 BulletKit (Lonza, MA), containing basal media
and growth factors, MEM (normal glucose) also containing 2mM L-glutamine and 1% non-
essential amino acids and DMEM (normal glucose) containing 2 mM L-glutamine. All media
were (if not specified otherwise) supplemented with 10% FBS, with the exception of the
EGM-2 BulletKit, which is delivered with an aliquot of 10 ml FBS to yield a final concentra-
tion of 2% FBS in solution.
In Vitro Cytotoxicity
The MTT assay [10] was employed to investigate the in vitro cytotoxicity of LTX-401 against a
selection of both cancer and non-malignant cell lines. Pre-cultured cells were seeded at a den-
sity between 1 x 104–1.5 x 104 cells/well, and the experiment was performed as previously
described [5]. The results were calculated using the mean of three experiments, each with tripli-
cate wells, and expressed as a 50% inhibitory concentration (IC50).
Hemolytic Activity
The cytotoxic activity of LTX-401 against human red blood cells (RBCs) was determined by a
hemolytic assay using freshly isolated blood from healthy individuals who gave their signed
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informed consent, and prepared as previously described [11]. RBCs were resuspended to a
10% hematocrit solution before being incubated for 1 h at 37°C with LTX-401 dissolved in
PBS at concentrations ranging from 136–1358 μM (50–500 μg/ml). RBCs with PBS and 1%
Triton solution alone served as a negative and positive control, respectively. After centrifug-
ing the samples at 4,000 rpm for 5 minutes, the absorbance of the supernatant was measured
at 405 nm on a spectrophotometric microliter plate reader (Thermomax Molecular Devices,
NJ, USA). The protocol used for blood sampling and handling has been reviewed by the
Regional Ethical Committee for Research Ethics at UiT, The Arctic University of Norway
(S1 File). The protocol is in accordance with international and local human research ethical
standards.
Kill Kinetics
The killing kinetics of LTX-401 were studied against B16F1 melanoma cells, using both the 2 x
IC50
4h and 4 x IC50
4h values corresponding to 54 μM and 108 μM, respectively. Cells were
seeded as previously described for MTT assay, and incubated with LTX-401 solutions for 5, 15,
30, 60, 90, 120 and 240 minutes. Cells were washed once with 100 μl of serum-free RPMI-1640
after incubation, and further incubated in a 10%MTT solution (diluted in a serum-free RPMI-
1640) for an additional 2 h.
TEM Electron Microscopy
B16F1 cells were seeded in 35 mm sterile tissue culture dishes at a density of 1 x 104 cells in a
volume of 2 ml of culture media, and left to adhere and grow in a cell incubator at 37°C,>95%
humidity and 5% CO2 conditions. When cultured cells reached an acceptable confluence
(*80–90%), they were incubated with the 4 x IC50
4h value of LTX-401 (108 μM) for different
time points (5, 15, 30 and 60 minutes) and subsequently fixed in a PHEM buffered (0.1 M)
solution containing 0.05% malachite green oxalate (Sigma), 0.5% glutaraldehyde (GA, Electron
Microscopy Sciences) and 4% formaldehyde (FA, Electron Microscopy Sciences). Malachite
green is more frequently being used as an additive to primary fixation in order to reduce lipid
Fig 1. Chemical structure of the small amphipathic β(2,2)-amino acid-derived antitumormolecule
LTX-401 (Mwnet = 367.53).
doi:10.1371/journal.pone.0148980.g001
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extraction commonly associated with sample processing [12, 13] and references cited [14].
Samples were immediately loaded and processed en bloc using the PELCO Biowave Pro Labo-
ratory Microwave (Ted Pella, Inc.), a newly introduced method considered to be advantageous
over conventional bench protocols, since it reduces sample preparation from days to hours.
For all microwave steps, samples were microwaved at 23°C with a 50°C cut-out temperature.
Both malachite green/GA/FA and osmium-reduced ferrocyanide (0.8% K3Fe(CN)6/1% OsO4)
fixation steps were run in “power on/off” cycles of 2 minutes on, 2 minutes off (100 W), with
vacuum. Samples were rinsed four times with 0.1 M PHEM buffer between each step (two
bench rinses and two final rinses for 40 seconds at 250 W) before being stained with 1% tannic
acid (Electron Microscopy Sciences, PA, USA) and 1% aqueous uranyl acetate (Electron
Microscopy Sciences, PA, USA) under “power on/off” cycles of 1 minute on, 1 minute off (150
W), with vacuum. Samples were rinsed as previously described between each staining proce-
dure, in addition to being microwaved twice in water at 250 W (vacuum off). The dehydration
of samples occurred through a graded ethanol series (25%, 50%, 70%, 90% and 100%), micro-
waving at 250 W for 40 seconds on each grade (vacuum off) before being immersed en bloc
with a 50% Epon resin (AGAR, DDSA, MNA and DNP-30), and increased to 100% for the two
final infiltration steps, 3 minutes each at 250 W (with vacuum cycle; 20 seconds on, 20 seconds
off). Samples were then polymerized overnight at 60°C. Ultrathin sections (70 nm) were pre-
pared and placed onto standard formvar, carbon-stabilized copper grids. Next, samples were
examined on a JEOL JEM-1010 transmission electron microscope, and images were taken
with an Olympus Morada side-mounted TEM CCD camera (Olympus soft imaging solutions,
GmbH, Germany).
Release of High Mobility Group Box 1 (HMGB1)
B16F1 cells were seeded at a density of 2 x105cells/well in 6-well plates in a complete medium,
and allowed to adhere overnight. Cells were treated with 108 μM of LTX-401 (4 x IC50
4h), and
incubated at 37°C (>95% humidity and 5% CO2) for different time points (10, 30, 60, 90 and
120 minutes). Serum-free RPMI 1640 was used as a negative control, and supernatants (S)
were collected and centrifuged at 1,400g for 5 min before being up-concentrated using Amicon
Ultra-0.5 Centrifugal Filter units with Ultracel-50 membrane (Milipore, Norway). Cell lysates
(L) were harvested after washing with 2 mL of serum-free RPMI-1640 and subjected to a lysis
buffer (mastermix) containing 2x NuPAGE LDS Sample buffer (Invitrogen, Norway), a 1x
NuPAGE Sample Reducing Agent (Invitrogen, Norway) and 50% sterile H20. Both superna-
tants and lysates were boiled at 70°C for 10 min and resolved on NuPAGE Novex 4–12% Bis-
Tris Gels (Millipore, Norway) before being electrotransferred to a polyvindiline difluoride
(PVDF) membrane (Millipore, Norway). Membranes were blocked for 1 h using 5% non-fat
dry milk in TBS-T and next hybridized with HMGB1 antibody (rabbit polyclonal to HMGB1 –
ChIP Grade, Abcam, UK) overnight at 4°C, followed by horseradish peroxidase- (HRP) conju-
gated secondary antibody (goat polyclonal anti-rabbit IgG, Abcam, UK) for an additional 2 h
at room temperature before being developed using WB Luminol Reagent (Santa Cruz Biotech-
nology, Heidelberg, Germany), and imaged/scanned using ImageQuant LAS 4000 and Image-
Quant software (GE Healthcare).
Release of Cytochrome c
B16F1 cells were plated onto 96-well culture plates as previously described above for the MTT
assay. Cells were treated with 108 μM (4 x IC50
4h) for designated time points (30, 60, 90, 120
and 240 minutes), while control cells were preserved in serum-free RPMI-1640 only until the
experimental endpoint. Supernatants were collected and diluted 1/5 in a serum-free RPMI
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1640 before being evaluated using a Rat/Mouse Cytochrome cQuantikine ELISA kit (R&D Sys-
tems, USA), according to the instructions of the manufacturer. The concentration of cyto-
chrome c was calculated by interpolation values on the provided standard curve.
Release of ATP
B16F1 cells were seeded as previously described for the MTT assay, and treated with the 2 x
IC50
4h value of LTX-401 (54 μM) for different time points (10, 30, 60, 90 and 120 minutes).
Serum-free RPMI 1640 treated cells functioned as a negative and blank control, respectively.
Extracellular levels of ATP were measured at the end of the experiment using a luciferin-based
ENLITEN ATP Assay kit (Promega, Madison, WI, USA), in which ATP-driven chemolumi-
nescence was recorded on a Luminescence Microplate Reader (Labsystems Luminoskan1, Fin-
land), and expressed as relative light units (RLU).
LysoTracker
Flow cytometry. B16F1 cells were seeded in 6-well plates and allowed to adhere overnight.
Cells were then treated with the 1 x IC50
4h of LTX-401 (27 μM) for 60 minutes, with 40 nM
LysoTracker DND-26 (Invitrogen) added in the last 5 minutes. Untreated cells were used as a
control. Cells were trypsinized and investigated on a FACS Calibur Flow cytometer, and the
results were processed using FlowJo Software (Tree Star, Inc., Ashland, OR, USA). PI was uti-
lized in some experiments to gate away cells with compromised plasma membrane.
Confocal microscopy. B16F1 cells were seeded in 8-well plates (Nunc) at 1 x 104 cells/well
and allowed to adhere overnight. Next, cells were treated with 27 μM of LTX-401 for 60 min-
utes and labelled with LysoTracker DND-26 for 5 minutes and with Hoecsht33342 for nuclear
staining. Cells were immediately investigated on a Zeiss Confocal microscope with a controlled
temperature and atmosphere.
Animals
Female C57BL/6 wild-type mice, 5–6 weeks old, were obtained from Charles River, United
Kingdom. All animals were housed in the same room and in cages (containing 2–5 mice) spe-
cially designed for mice, with a 12h/12h day-night cycle, and allowed ad libitum access to high
quality food and water. Each cage contained environmental enrichments such as nest material,
chewing sticks and housing. Animals were weighed weekly and monitored several times per
week, and no unexpected deaths were observed. All experiments were approved by the Norwe-
gian National Animal Research Authority (NARA), and conducted in accordance with local
and European Ethical Committee guidelines, NARA approval ID: 6586.
Tumor Treatment
B16F1 cells were harvested, washed in serum-free RPMI and injected intradermally (i.d) into
the right side of the abdomen in C57BL/6 mice (7.5 x 104 B16F1 cells per mouse/50 μl RPMI-
1640). Palpable tumors (20–30 mm2) were injected intratumorally (i.t) with either LTX-401 or
a vehicle (saline) once per day for three consecutive days (Fig 2). Animals were euthanized
according to humane endpoints such as a weight loss of>10%, general physical discomfort or
reduced activity, severe tumor necrosis or ulceration, or if the tumor size exceeded 130 mm2.
All animals were euthanized using cervical dislocation.
Anticancer Effect of a Cytolytic Amphipathic β(2,2)-Amino Acid Derivative
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Histological Examination
Tumors were fixated by perfusion using ZN2+ fixative. After fixation and paraffin embedding,
sections were deparaffinized using xylene and graded alcohol before hydration and washing
with PBS. Antigen retrieval was performed in a sodium citrate buffer (pH 6) in a microwave
oven, and endogenous peroxidase was subsequently blocked by 0.3% H2O2. Sections were incu-
bated overnight at 4°C with a primary antibody (rabbit anti-CD3; Dako). An anti-rabbit-horse-
radish peroxidase SuperPicTure Polymer detection kit (Invitrogen, San Francisco, CA, USA)
was used as a secondary antibody. A matched isotype control was used as a control for non-
specific background staining, and a routine standard staining was performed with hematoxylin
and eosin.
Statistical Analysis
Results are presented as a mean ± standard error of mean (SEM) or standard deviation (SD) of
at least two independent experiments. MTT assays were conducted twice with three parallels
and cytochrome c assays were conducted twice with two parallels, while ATP assays were con-
ducted three times with two parallels. Cytochrome c release- and ATP release data were com-
pared using one-way ANOVA and a multiple comparison test, and we considered a P-value
0.05 to be considered statistically significant. Animal survival plots were tested for signifi-
cance using a Mantel-Cox test.
Results
LTX-401 Rapidly Induces Cell Death
In this study, LTX-401 effectively reduced the viability of several tumor cell lines in vitro, with
a similar degree of cytotoxicity against non-malignant cell lines such as HUV-EC-C endothelial
cells, HaCat keratinocytes and MRC-5 fibroblasts (Table 1). LTX-401 displayed the highest
cytotoxic activity against the human malignant melanoma cell line MDA-MB-435S (13.5 μM),
and was least active against the human hepatocellular carcinoma cell line HEPG2 (35.4 μM).
For the remaining cell lines, LTX-401 exhibited similar IC50 values, varying slightly within the
range of 19–32 μM. No in vitro hemolytic activity against RBCs was observed using the same
concentrations required for the induction of cell death in cancer cell lines. A 50% hemolysis
was observed using higher concentrations of LTX-401 (400 μg/ml = 1087 μM) (Table 1).
Kinetic experiments were performed to determine the time course of the cytotoxic activity
of LTX-401 against B16 melanoma cells. Two different concentrations representing the 2 x
IC50
4h and 4 x IC50
4h of LTX-401, i.e. 54 μM and 108 μM, respectively, were used to assess the
dose-dependent effect. As revealed by initial pilot studies, these two concentrations were also
employed for the majority of in vitro experiments, and in particular when studying the release
of DAMPs, as lower concentrations failed to induce such a modality.
LTX-401 (108 μM) exhibited rapid killing kinetics, with a kill ratio of 50% after 15 min, fol-
lowed by nearly 100% cell death two hours after start of treatment. In contrast, cells incubated
Fig 2. Tumor-treatment schedule.
doi:10.1371/journal.pone.0148980.g002
Anticancer Effect of a Cytolytic Amphipathic β(2,2)-Amino Acid Derivative
PLOS ONE | DOI:10.1371/journal.pone.0148980 February 16, 2016 6 / 19
with 54 μM of LTX-401 followed a gradual inhibition of cell viability, with a 50% cell survival
after two hours (Fig 3).
LTX-401 Treatment Causes Ultrastructural Changes in Melanoma Cells
To further investigate the mode of action underlying the cytotoxic activity of LTX-401, B16F1
cells were incubated with the 4 x IC50
4h of LTX-401 (108 μM) for 5 and 60 min, respectively.
Untreated cells served as a control, and were incubated in a serum-free RPMI 1640 until the
experimental endpoint (60 min). After incubation, all cells were fixed and prepared for TEM
studies. TEM images of untreated B16F1 cells revealed a rough surface characterized by fre-
quent microvillus-like protrusions on the plasma membrane (Fig 4A and 4B). The cytoplasm
consisted of several electron-dense mitochondria, and visibly smooth ER and Golgi apparatus
(Fig 4A and 4B). The majority of LTX-401 treated cells lost their surface morphology after 5
min, and the majority of cells were without significant alterations except for a slight vacuoliza-
tion of the cytoplasm (Fig 4C). After 60 minutes of incubation, treated cultures demonstrated a
heterogeneous population of cells, including both heavily vacuolated and large non-vacuolated
cells (Fig 4E). Large portions of cells were necrotic, as was clearly seen by the loss of plasma
membrane integrity and leakage of cell constituents (Fig 4E and 4F). The chromatin structure
was more or less unaffected by LTX-401 treatment, albeit slightly condensed in a number of
cells. Furthermore, a higher magnification revealed no significant ultrastructural changes in
the mitochondria of the majority of LTX-401 treated cells (Fig 4H) compared to controls (Fig
4G). Cells treated for 60 minutes (Fig 4H) displayed intact inner and outer mitochondrial
membranes, albeit with some degree of mitochondrial swelling. Overall, these observations
demonstrate that LTX-401 kills by a lytic mode of action, accompanied by cellular swelling,
mitochondrial swelling and vacuolization of the cytoplasm.
LTX-401 Treatment Results in the Release of DAMPs in Melanoma Cells
Next, we wanted to characterize the ability of LTX-401 to induce the release of DAMPs.
HMGB1 is a non-histone nuclear protein, and when released extracellularly it can act as a
Table 1. LTX-401 is active against a range of different cancer cells, but exhibits a low hemolytic activ-
ity. Data from three or more experiments are presented as mean ±SD. IC50 is the inhibitory concentration,
resulting in a killing of 50% of the cells.
Cell lines LTX-401 IC50
a ± SD (μM)
JM1 (Rat hepatocellular carcinoma) 22.8 ± 3.3
HEPG2 (Human hepatocellular carcinoma) 35.4 ± 0.6
BEL7402 (Human hepatocellular carcinoma) 26.7 ± 0.4
B16F1 (Murine skin malignant melanoma) 23.3 ± 3.9
MDA-MB-435S (Human malignant melanoma) 13.5 ± 1.4
Malme-3M (Human malignant melanoma) 19.3 ± 0.4
HT-29 (Human colorectal adenocarcinoma) 31.7 ± 2.9
A375 (Human skin malignant carcinoma) 30 ± 0.9
SK-N-AS (Human neuroblastoma) 30.6 ± 0
MRC-5 (Human lung fibroblasts) 22.9 ± 1.4
HUV-EC-C (Human vascular endothelium) 18.4 ± 1.9
HaCat (Human keratinocytes) 22 ± 2.2
RBC (Human) >1087
a The peptide concentration killing 50% of the cells
doi:10.1371/journal.pone.0148980.t001
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DAMP by binding to toll-like receptors (TLRs) or receptor for advanced glycation end-prod-
ucts (RAGE) [15]. The release of HMGB1 from B16F1 cells into cell culture supernatants was
assessed by Western blot analysis. The translocation of HMGB1 was detected, with the release
of HMGB1 occurring after 30 min of treatment. Non-treated control cells displayed no release
of HMGB1 into the supernatant, as seen by the complete detainment of the protein within the
lysates (Fig 5A).
Cytochrome c is considered a mitochondrial-derived DAMP [16], and extracellular cyto-
chrome c has been reported to induce NF-kB activation and the release of proinflammatory
cytokines [17]. To study whether LTX-401 was able to induce the release of cytochrome c from
LTX-401-treated B16F1 cells, an ELISA assay was employed to measure the amounts of cyto-
chrome c in the cell culture medium after treatment. A quantitative analysis demonstrated the
presence of cytochrome c in the supernatant following LTX-401 treatment with the 4 x IC50
4h
value of LTX-401 (108 μM) (Fig 5B) after 120 min of treatment. The release of cytochrome c
followed a gradual increase over time, reaching a peak of approximately 40 ng/ml at the experi-
mental endpoint (Fig 5B).
ATP is reported to have immunogenic properties when released from dying and/or stressed
cells, including cancer cells succumbing to conventional chemotherapy [18, 19]. To investigate
Fig 3. LTX-401 rapidly induces cell death in B16F1melanoma cells. The determination of cell viability after a short incubation at two different
concentrations of LTX-401 was analyzed after designated time points (5, 15, 30, 60, 90, 120 and 240 minutes), which revealed a decreased viability after 60
minutes of incubation. Data represent three experiments performed in triplicate presented for each time point as mean ± SEM.
doi:10.1371/journal.pone.0148980.g003
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whether LTX-401 was able to induce the release of ATP from B16F1 cells, a luciferin-lucifer-
ase-based reaction assay was employed. The extracellular concentration of ATP quickly rose 60
min after initiating treatment with a gradual increase towards 120 min (Fig 5C).
Treatment with LTX-401-Induced Loss of Lysosomal Integrity in
Melanoma Cells
Next, we wanted to investigate whether LTX-401 caused any changes in lysosomal integrity.
Treatment with LTX-401 resulted in a loss of signal from the acidophilic dye LysoTracker
DND-26, as shown with flow cytometry and confocal microscopy. This dye accumulates in
acidic organelles such as lysosomes and melanosomes. The effect was shown not to be cell-
type specific, as similar results were also obtained in lymphoma cells (data not shown). As
demonstrated by both flow cytometry and confocal microscopy, 27 μM of LTX-401 induced a
decreased signal in B16F1 melanoma cells after 60 minutes of incubation (Fig 6A and 6B).
Fig 4. LTX-401 treatment induced ultrastructural changes with vacuolization.Representative TEMmicrographs of B16F1 cells treated with LTX-401
(108 μM). Untreated control cells (A and B) were kept in a serum-free RPMI 1640 only until the experimental endpoint (60 minutes), and compared with cells
treated for both 5 min (C and D) and 60 min (E and F); scale bars = 10 μm for A, C, E, 5 μm for B, D, F.
doi:10.1371/journal.pone.0148980.g004
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Fig 5. LTX-401 induces the release of danger signals. (A) Release of HMGB1 into the supernatant of LTX-
401-treated cells as determined with Western blot. Translocation of the nuclear protein HMGB1 from the cell
lysate (L) to the culture supernatant (S) was evident after 30 minutes of treatment with LTX-401 (108 μM),
and the translocation was absolute after 90 minutes of incubation. Control cells showed no translocation after
240 minutes. Experiment was conducted thrice, and this figure is a digital image of a representative blot; (B)
Anticancer Effect of a Cytolytic Amphipathic β(2,2)-Amino Acid Derivative
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Intratumoral Injection of LTX-401 Leads to Complete Regression of
B16F1 Murine Melanoma
To assess the antitumor effects of LTX-401 in vivo, palpable B16 melanomas were injected i.t
with LTX-401 (or vehicle only) once a day for three consecutive days. The majority (9/11) of
the animals demonstrated a complete and lasting tumor regression after intratumoral treat-
ment with LTX-401 (Fig 7A).
To study the underlying mechanisms behind tumor regression, tumors were dissected for
histological analysis. Samples were collected from selected animals in the treatment group and
control group on days 2 and 7 post-treatment with a single i.t injection. The immunolabelling
of tumor tissue with anti-CD3 antibody revealed that a majority of the infiltrating cells were
CD3+ T cells, whereas tumors injected with vehicle only exhibited tumors with a viable tumor
tissue, with minimal necrosis and few lymphocytes (Fig 7B)
Discussion
The ability of cancer cells to evade immunosurveillance has recently been acknowledged as an
emerging hallmark of cancer [20]. Immunogenic cell death (ICD) is defined as the release of
immune-potentiating molecules termed danger-associated molecular pattern molecules
(DAMPs), and thus is critical in establishing an immune response against cancer cells [21].
Due to the ability of some cytostatic compounds to induce ICD [18, 22], it has also been shown
that the immune system plays an important role in cancer eradication as a response to conven-
tional treatment. ICD has additionally been suggested as a determinant for the long-term
success of anticancer therapies [21]. Oncolytic therapy is a new and promising therapeutic
approach against solid tumors, where cancer cells are lysed in situ with the subsequent release
of DAMPs [5, 23–25].
The recently designed amino acid derivative LTX-401 has been reported to exhibit antican-
cer activity [26]. In the present study, we demonstrate that LTX-401 exerts anticancer activity
against a range of cancer cell lines, including B16 melanoma (Table 1). However, LTX-401 is
also active against normal endothelial cells, keratinocytes and fibroblasts, but displays a low
hemolytic activity (Table 1). We have previously designed shorter peptides with the potential
to adopt an α-helical coil structure based on structure-activity relationship studies (SAR) on
bovine lactoferricin (LfcinB) derivatives. These peptides have been shown to kill cancer cells
more effectively than the naturally occurring LfcinB (25-mer), both in vitro and in vivo [5, 23].
SAR studies revealed that the size of the aromatic sector, and hence the overall higher hydro-
phobicity, is an important factor that will potentiate the anticancer activity of the peptide, but
it could also increase the efficacy against untransformed cells (Fig 1) [27, 28]. This is supported
by recent observations, in which anticancer peptides with greater hydrophobicity were less
selective and displayed more cytotoxicity against normal cells [29, 30]. Such a structural
parameter may explain in part the lack of selectivity, and hence an unspecific targeting of also
non-malignant cells by LTX-401, as the two aromatic side chains give it a high hydrophobicity,
thereby making it more prone to interact with phospholipid bilayers. Furthermore, it is likely
that the low positive charge of LTX-401 (+2) reduces its capacity of binding strongly to anionic
surface components on cancer cells via electrostatic forces. It is plausible that a higher
B16F1 cells were treated with LTX-401 (108 μM) for different time points (30, 60, 90, 120 and 240 minutes)
before determining the amount of cytochrome c in supernatants using an ELISA assay. The results are
presented as mean +/- SEM; (C) B16F1 cells were treated with LTX-401 (54 μM) for designated time points
(10, 30, 60, 90 and 120 min). The quantification of ATP level was performed by luciferase bioluminescence,
and the results are presented as mean +/- SEM.
doi:10.1371/journal.pone.0148980.g005
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Fig 6. LTX-401 treatment induced loss of lysosomal integrity. (A) B16F1 cells were treated with LTX-401 (27 μM) for 60 minutes before determining the
signal strength from LysoTracker (DND-26) using flow cytometry. The figure is representative for one of three conducted experiments; (B) B16F1 cells were
treated with LTX-401 (27 μM) for 60 minutes, and the signal from LysoTracker was imaged using confocal microscopy (z-stack, maximum intensity
projection).
doi:10.1371/journal.pone.0148980.g006
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Fig 7. Intratumoral treatment induced complete regression in B16F1melanomas. (A) The intratumoral treatment of murine melanoma induced a rapid
and complete regression in 9/11 animals, and offered long-term protection against a rechallenge in the majority of the cured mice. Palpable B16F1 tumors
were injected with either a sterile 0.9% NaCl (vehicle controls) or 5 mg/ml LTX-401 once a day for three consecutive days. P<0.0001 (Mantel-Cox test); (B)
Infiltrating CD3+ lymphocytes were detected in tumors following one single injection of LTX-401 (7 days post-injection) in a murine experimental animal
model.
doi:10.1371/journal.pone.0148980.g007
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cationicity would therefore render non-malignant cells less susceptible to killing, but since
LTX-401 is proposed to be used in the local treatment of solid tumors, the selectivity against
cancer cells is less important, in contrast to anticancer drugs designed for systemic use.
Kinetic experiments were conducted in order to study the impact of different concentrations
of LTX-401 against B16F1 melanoma cells over time. The concentrations used in the kinetic
studies represented the 2 x IC50
4h and 4 x IC50
4h values. The cellular survival was reduced to a
minimum after 90–120 min of using the 4 x IC50
4h value (108 μM) (Fig 3). By contrast, com-
monly used chemotherapeutic agents require longer incubation periods to exert a significant
anticancer effect [6].
To study the morphological changes of LTX-401 treated cancer cells, transmission electron
microscopy (TEM) studies were performed. These studies revealed an early loss of surface mor-
phology and a slight vacuolization of the cytoplasm of treated B16F1 cells (Fig 4C and 4D). An
increase in cell size was also evident shortly after the start of LTX-401 treatment. By prolonging
the incubation period of treated cells (to 60 min), TEM images demonstrated an increased
vacuolization, and revealed that cells were killed by a lytic mode of action that resulted in a loss
of cell membrane integrity and the subsequent leakage of intracellular contents into the extra-
cellular milieu (Fig 4E and 4F).
The formation of vacuoles containing cytoplasmic material may constitute a transitional
state in which cells respond to acute intracellular stress exerted by LTX-401 on different organ-
elles. The mitochondria displayed normal morphology five minutes post treatment, while
showing evidence of swelling at experimental endpoint (60 min). In all the samples, the cells
displayed a heterogeneous morphology, and we observed differences between individual cells
among healthy control cells. Cell lines derived from the B16 cell line are known to consist of a
heterogeneous population of both spindle-shaped and epithelial-like cells [31, 32]. These differ-
ent phenotypes could possibly respond differently to treatment with anticancer substances,
including LTX-401, which may partially explain the heterogeneous morphology of the treated
cells.
When the concept of immunogenic cell death (ICD) was introduced, it was recognized that
the mode of cancer cell death plays an important role in determining the outcome and success
of selected anticancer therapies, including radiotherapy and several commonly used chemo-
therapeutic regimens [18, 33, 34]. The activation of potent anti-tumor immune responses has
been shown to rely on a series of cellular and biochemical events culminating in the release of
DAMPs from dying and/or stressed tumor cells, including surface-exposed calreticulin (CRT),
secreted adenosine triphosphate (ATP) and passively released High Mobility Group Box-1 pro-
tein (HMGB1). These three molecules are considered the hallmarks of ICD [21, 35]. When
interacting with their respective receptors, DAMPs, along with tumor antigens, may orches-
trate the recruitment and activation of dendritic cells (DCs) into the tumor bed, which may
later home to draining lymph nodes to active tumor-specific CD8+ T cells [15, 36, 37]. In the
present study, B16F1 melanoma cells treated with LTX-401 in vitro were screened for the
release of ATP and HMGB1 using a luciferase assay and Western blot analysis, respectively.
These experiments revealed that LTX-401 treatment induced the release of HMGB1 and ATP
in B16F1 cells (Fig 5A and 5C). The translocation of HMGB1 from the intracellular compart-
ment into the supernatant was evident in B16F1 cells treated with LTX-401. The extracellular
release of HMGB1 from post-apoptotic and/or necrotic cells is capable of sustaining and aug-
menting an anti-tumorigenic environment by the attraction of inflammatory leukocytes and
the stimulation of pro-inflammatory cytokines such as TNF-α and IL-6 [38, 39]. In addition,
HMGB1 serves a pivotal role in the maturation of DCs and favors both processing and the pre-
sentation of tumor antigens to naïve T cells, thereby establishing a link between innate and
adaptive anti-tumor immune responses [33, 40, 41]. However, the release of HMGB1 from
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dying cancer cells is not solely consistent with the establishment of anti-tumor immune
responses as redox modifications induced by the cell or in the extracellular milieu, which may
alter and even attenuate its DAMP activities [42, 43].
When an ATP is released or secreted into the extracellular milieu by tumor cells, it acts on
purinergic receptors to help facilitate the recruitment of immune cells into the tumor bed [44].
Moreover, when binding to P2X7 receptors on DCs, ATP stimulates the assembly of NLRP3
inflammasome, and initiates a series of downstream events that ultimately result in the produc-
tion and release of IL-1β, a cytokine required for the priming of IFN-γ producing tumor-spe-
cific CD8+ T cells [45–47]. ATP was released from B16F1 in an increasing manner during the
experimental time period.
Mitochondrial DAMPs (mtDAMPs) include ATP, mitochondrial DNA, formyl peptides,
oxidized cardiolipin and cytochrome c [16]. These molecules are considered to be potent
immune activators, as mitochondria bears a striking resemblance to bacteria [16]. Cytochrome
cmarks one of the early events during apoptotic cell death, in which its release from the mito-
chondrial intermembrane space into the cytosol controls the assembly of the apoptosome and
activation of procaspase-9, thus acting like an intracellular danger signal [48]. The release of
cytochrome c is also reported to occur from cells succumbing to necrosis [49]. Furthermore,
extracellular cytochrome c induces the activation of NF-kB and the release of other proinflam-
matory cytokines and chemokines [17]. Elevated serum levels of cytochrome c have been
observed in SIRS patients and are linked to poor survival [50]. A cytochrome c ELISA assay
was performed to help assess the capability of LTX-401 to release mtDAMPs. Treatment with
LTX-401 was shown to induce the extracellular release of cytochrome c from B16F1 melanoma
cells in vitro (Fig 5B). Interestingly, while TEMmicrographs confirmed the lysis of B16F1 cells
after 60 min, the release of cytochrome c was not significantly different from controls until
after 120 min, which could indicate that the mitochondria is still somewhat intact and contin-
ues to retain its cytochrome c for a while after cell lysis.
The electron microscopy studies support the notion that mitochondria in B16F1 cells are
not initially affected by LTX-401 treatment, and the timing of cytochrome c release could
imply that the lysis of the mitochondria is secondary to the lysis of the cell. Previous mode of
action studies by Ausbaucher et al. supports these findings, in which LTX-401 did not compro-
mise the mitochondrial membrane potential as measured by TMRE [51].
However, LTX-401 is a small molecule with an amphipathic structure, thus possessing the
potential to bypass the plasma membrane, subsequently targeting intracellular structures. We
therefore wanted to investigate other potential intracellular targets involved. The effect of LTX-
401 treatment on acidic organelles was assessed by the use of lysosomal dye LysoTracker
DND-26, with the confocal imaging of live cells demonstrating that LTX-401 treatment signifi-
cantly altered the fluorescence of the acidophilic dye LysoTracker, even before gross morpho-
logical changes occurred. This observation was confirmed using flow cytometry analysis with
the same concentrations and incubation time (Fig 6). The loss of fluorescence indicates that
acidic organelles in the cells are compromised due to treatment. Even so, B16F1 cells also har-
bor melanosomes, which are acidic lysosome-related organelles. Consequently, we repeated the
experiment in a non-melanocytic cell line (A20, murine lymphoma), and achieved similar
results (data not shown). These findings suggest that the lysosomes are among the intracellular
targets of LTX-401.
To help assess the anticancer effects of LTX-401 against highly aggressive and poorly immu-
nogenic B16 melanomas, established tumors were treated by intratumoral injections of LTX-
401 (5 mg/ml) once a day for three consecutive days. The majority of treated animals displayed
a complete regression of intradermally established tumors (Fig 7A). Histological examinations
of tumors treated with LTX-401 revealed an increased infiltration of CD3+ T cells (Fig 7B).
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This indicates that the cytolytic effect exerted by LTX-401 provides a favorable immunogenic
environment in situ, thus resulting in the infiltration of lymphocytes.
Immunotherapeutic strategies aim to mount a specific T-cell response against tumor cells.
Intratumoral immunotherapy for melanoma is a promising approach, with several preclinical
and clinical trials reporting exciting results [25, 52–57]. In our study, we have investigated the
anticancer efficacy and mode of action of a small lytic amino-acid derivative LTX-401. Mela-
noma cells treated with LTX-401 demonstrated features of immunogenic cell death, as shown
by the release of DAMPs such as ATP, HMGB1 and cytochrome c. Furthermore, LTX-401
induced complete regression of highly aggressive and poorly immunogenic murine B16 mela-
nomas. In conclusion, our results demonstrate the potential of LTX-401 as a promising immu-
notherapeutic agent.
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